Silverfin false false 31/12/2024 01/01/2024 31/12/2024 J Mccomb 06/09/2017 30 September 2025 The principal activity of the Company continued to be that of research and experimental development on biotechnology. SC575642 2024-12-31 SC575642 bus:Director1 2024-12-31 SC575642 2023-12-31 SC575642 core:CurrentFinancialInstruments 2024-12-31 SC575642 core:CurrentFinancialInstruments 2023-12-31 SC575642 core:Non-currentFinancialInstruments 2024-12-31 SC575642 core:Non-currentFinancialInstruments 2023-12-31 SC575642 core:ShareCapital 2024-12-31 SC575642 core:ShareCapital 2023-12-31 SC575642 core:CapitalRedemptionReserve 2024-12-31 SC575642 core:CapitalRedemptionReserve 2023-12-31 SC575642 core:RetainedEarningsAccumulatedLosses 2024-12-31 SC575642 core:RetainedEarningsAccumulatedLosses 2023-12-31 SC575642 core:LeaseholdImprovements 2023-12-31 SC575642 core:PlantMachinery 2023-12-31 SC575642 core:ComputerEquipment 2023-12-31 SC575642 core:LeaseholdImprovements 2024-12-31 SC575642 core:PlantMachinery 2024-12-31 SC575642 core:ComputerEquipment 2024-12-31 SC575642 bus:OrdinaryShareClass1 2024-12-31 SC575642 2024-01-01 2024-12-31 SC575642 bus:FilletedAccounts 2024-01-01 2024-12-31 SC575642 bus:SmallEntities 2024-01-01 2024-12-31 SC575642 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 SC575642 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 SC575642 bus:Director1 2024-01-01 2024-12-31 SC575642 core:LeaseholdImprovements core:TopRangeValue 2024-01-01 2024-12-31 SC575642 core:PlantMachinery core:TopRangeValue 2024-01-01 2024-12-31 SC575642 core:ComputerEquipment core:TopRangeValue 2024-01-01 2024-12-31 SC575642 2023-01-01 2023-12-31 SC575642 core:LeaseholdImprovements 2024-01-01 2024-12-31 SC575642 core:PlantMachinery 2024-01-01 2024-12-31 SC575642 core:ComputerEquipment 2024-01-01 2024-12-31 SC575642 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 SC575642 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: SC575642 (Scotland)

BIOCLAVIS LIMITED

UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH THE REGISTRAR

BIOCLAVIS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

Contents

BIOCLAVIS LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2024
BIOCLAVIS LIMITED

BALANCE SHEET (continued)

AS AT 31 DECEMBER 2024
Note 2024 2023
£ £
Fixed assets
Tangible assets 3 142,114 244,241
142,114 244,241
Current assets
Debtors
- due within one year 4 357,728 396,914
- due after more than one year 4 23,461 23,461
Cash at bank and in hand 685,216 697,474
1,066,405 1,117,849
Creditors: amounts falling due within one year 5 ( 133,111) ( 187,600)
Net current assets 933,294 930,249
Total assets less current liabilities 1,075,408 1,174,490
Net assets 1,075,408 1,174,490
Capital and reserves
Called-up share capital 6 170,085 170,085
Capital redemption reserve 30,015 30,015
Profit and loss account 875,308 974,390
Total shareholder's funds 1,075,408 1,174,490

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of BioClavis Limited (registered number: SC575642) were approved and authorised for issue by the Director on 30 September 2025. They were signed on its behalf by:

J Mccomb
Director
BIOCLAVIS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024
BIOCLAVIS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

BioClavis Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Scotland. The address of the Company's registered office is Carus House Dumbarton Road, 201 Ground Floor, Clydebank, G81 4XJ, Scotland, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Leasehold improvements 5 years straight line
Plant and machinery 3 years straight line
Computer equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities
Basic financial liabilities, including creditors and bank loans, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including the director 11 13

3. Tangible assets

Leasehold improve-
ments
Plant and machinery Computer equipment Total
£ £ £ £
Cost
At 01 January 2024 205,679 482,143 112,644 800,466
Additions 0 12,159 3,506 15,665
Disposals 0 ( 2,831) 0 ( 2,831)
At 31 December 2024 205,679 491,471 116,150 813,300
Accumulated depreciation
At 01 January 2024 63,364 408,626 84,235 556,225
Charge for the financial year 41,136 59,961 16,687 117,784
Disposals 0 ( 2,823) 0 ( 2,823)
At 31 December 2024 104,500 465,764 100,922 671,186
Net book value
At 31 December 2024 101,179 25,707 15,228 142,114
At 31 December 2023 142,315 73,517 28,409 244,241

4. Debtors

2024 2023
£ £
Debtors: amounts falling due within one year
Trade debtors 338,001 380,234
Other debtors 19,727 16,680
357,728 396,914
Debtors: amounts falling due after more than one year
Other debtors 23,461 23,461

5. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 103,307 120,639
Other taxation and social security 13,806 37,417
Other creditors 15,998 29,544
133,111 187,600

6. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
170,085 Ordinary shares of £ 1.00 each 170,085 170,085